10-Q: TransCode Therapeutics Reports Q2 2025 Results, Advances Clinical Trial

TransCode Therapeutics reported increased net loss for the first half of 2025 despite reduced operating expenses, while its lead cancer therapeutic candidate, TTX-MC138, showed positive safety data in its Phase I/II clinical trial.

Summary

• Net loss for the six months ended June 30, 2025, increased to $16.4 million from $8.5 million in the same period of 2024, primarily due to a non-cash change in fair value of warrant liabilities.
• Operating expenses decreased by $1.01 million for the six months ended June 30, 2025, compared to the same period in 2024, driven by reductions in R&D and G&A expenses.
• Cash on hand at June 30, 2025, was $7.4 million, an increase from $5.8 million at December 31, 2024, primarily due to financing activities.
• The company successfully raised approximately $8.9 million in net proceeds from an equity financing in March 2025.
• The Phase I/II clinical trial for TTX-MC138 is progressing, with dosing approved for the fourth cohort and no significant safety or dose-limiting toxicities reported in Cohorts 1, 2, 3, or 4.
• TransCode Therapeutics was deemed in compliance with Nasdaq's minimum bid price requirement of $1.00 per share on June 2, 2025.
• The company implemented further restructuring actions, including terminating a sublease, reducing headcount to seven employees, and relocating business activities to short-term office space.
• The collaboration agreement with MD Anderson was amended to focus solely on participation in the Phase I/II clinical trial, relieving the company of a $10 million payment obligation.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While clinical trial progress and Nasdaq compliance are positive, the significant increase in net loss, higher cash burn, and explicit 'going concern' warning, coupled with the short cash runway, indicate substantial financial challenges and high risk.

Positives

• Phase I/II clinical trial for TTX-MC138 is advancing, with dosing approved for the fourth cohort and preliminary data indicating no significant safety or dose-limiting toxicities in Cohorts 1-4.
• PK and PD data from Cohorts 1 and 2 of the clinical trial are consistent with preclinical results and Phase 0 clinical trial findings, supporting the TTX pipeline's drug delivery validity.
• Nasdaq confirmed compliance with the minimum bid price rule on June 2, 2025, ensuring continued listing.
• General and administrative expenses decreased by $955 thousand for the six months ended June 30, 2025, reflecting cost management efforts.
• Research and development expenses saw a slight decrease of $55 thousand for the six months ended June 30, 2025, despite ongoing clinical trial activities.
• Grant income significantly increased to $501,529 for the six months ended June 30, 2025, from $27,057 in the prior year, due to a new NIH award.
• The collaboration agreement with MD Anderson was amended, relieving the company from a commitment to fund up to $10 million in collaboration payments.

Negatives

• Net loss for the six months ended June 30, 2025, increased significantly to $16.4 million, compared to $8.5 million for the same period in 2024.
• Net cash used in operating activities increased to $7.3 million for the six months ended June 30, 2025, from $6.3 million in the prior year, indicating a higher cash burn.
• The company has not generated any revenue from product sales since inception and does not expect to in the foreseeable future.
• Management believes existing cash of $7.4 million is sufficient only into the fourth quarter of 2025 and not for a full 12 months from the financial statement issuance date.
• Substantial doubt exists about the company's ability to continue as a going concern without additional capital.
• The company has an accumulated deficit of approximately $79.6 million as of June 30, 2025.
• Material weaknesses in internal control over financial reporting were identified prior to the IPO and remain unremediated, posing risks to accurate financial reporting.

Risks

• Inability to obtain additional financing on acceptable terms or at all, which could lead to scaling back operations or relinquishing technology rights.
• Potential delisting of common stock from the Nasdaq Capital Market, which would reduce liquidity, adversely affect value, and make capital raising more difficult.
• Substantial doubt about the company's ability to continue as a going concern within one year without additional capital.
• Uncertainty regarding the results and timing of preclinical and clinical trial activities, including patient enrollment.
• Adverse global conditions, including economic uncertainty, tariffs, geopolitical conflicts (Ukraine, Middle East), and pandemics, could negatively affect financial results and operations.
• Potential changes in regulatory requirements and delays or negative outcomes from the regulatory approval process for therapeutic candidates.
• Reliance on third parties for clinical trial planning, conduct, management, monitoring, and manufacturing of drug supplies.
• Inability to protect intellectual property or operate without infringing on others' IP rights.
• Challenges in attracting, retaining, and motivating key personnel.
• Inability to generate revenue and achieve profitability, leading to potential reduction or termination of operations.
• Impact of new or revised U.S. tax laws, such as Section 174 of the IRC regarding R&D expense capitalization, which could adversely affect cash flow.
• Inability to adequately protect information systems from cyberattacks, potentially leading to disclosure of confidential information, reputational damage, and financial/legal exposure.
• Claims by an investment bank for fees, which the company rigorously disputes, could result in legal proceedings.

Future Outlook

The company expects expenses and capital requirements to increase substantially with ongoing preclinical studies and additional clinical trials for TTX-MC138. It anticipates needing substantial additional funding through equity, debt, or collaborations to support operations beyond the fourth quarter of 2025. The ability to generate product revenue and achieve profitability is highly uncertain, and failure to raise capital could lead to significant delays, reductions, or termination of development programs, potentially resulting in a total loss for common stockholders.

Management Comments

• Management believes that cash at June 30, 2025, is sufficient to fund operations and capital requirements into the fourth quarter 2025, but not for a full 12 months from the date of issuance of these financial statements.
• The company has concluded there is substantial doubt concerning its ability to continue as a going concern within one year of the issuance of these financial statements without additional capital becoming available.
• The company plans to fund its operations by continuing to raise additional capital, primarily through sales of equity or debt, and from funds that may be awarded under government and other grants.
• The company believes its TTX platform can further be used for developing targeted radiolabeled therapeutics and diagnostics and other custom products targeting known and novel biomarkers and other genetic elements as they are discovered and validated.
• The company believes the TTX platform is designed to overcome extracellular and intracellular delivery issues of stability, efficiency, and immunogenicity faced by existing lipid and liposomal nanoparticle platforms.

Industry Context

TransCode Therapeutics operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically focusing on RNA therapeutics for oncology. The challenge of effective RNA delivery to tumor cells is a significant hurdle in the field, and TransCode's proprietary TTX platform aims to address this. The company's clinical-stage status with TTX-MC138 positions it among numerous biotech firms vying for breakthroughs in cancer treatment. The reliance on external financing and grants is typical for early to mid-stage biopharma companies, and the ongoing clinical trial progress, particularly positive safety data, is a critical step in de-risking its lead candidate in a sector where clinical success is paramount for valuation and future funding.

Comparison to Industry Standards

• As a clinical-stage biopharmaceutical company without product revenue, TransCode's financial performance is not directly comparable to revenue-generating industry leaders. Its accumulated deficit of $79.6 million and recurring losses are typical for companies in the R&D phase.
• The cash runway into Q4 2025, with a stated need for additional capital within 12 months, is a common challenge for small-cap biotech firms, often necessitating frequent capital raises. This is similar to other early-stage oncology companies like OncoSec Medical (ONCS) or Checkpoint Therapeutics (CKPT) which frequently raise capital to fund clinical programs.
• The progress of TTX-MC138 through Phase I/II with no significant safety or dose-limiting toxicities is a positive indicator, aligning with the initial safety objectives of early-phase clinical trials. This is a crucial step, comparable to early-stage clinical data releases from peers such as Arbutus Biopharma (ABUS) or Dicerna Pharmaceuticals (DRNA) in the RNAi space, where safety and tolerability are key de-risking factors.
• The company's restructuring efforts, including headcount reduction and facility changes, reflect a common strategy among smaller biotechs to extend cash runway and optimize operational efficiency during challenging funding environments, similar to actions taken by companies like Finch Therapeutics (FNCH) or Atea Pharmaceuticals (AVIR) in recent years.

Management Changes

Corporate Governance

Legal Proceedings

• The company is rigorously disputing claims by an investment bank that it is entitled to fees. No other material claims or actions are pending or threatened.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity financings and potential total loss of investment if the company undergoes restructuring due to inability to raise capital. The reverse stock split and Nasdaq compliance offer temporary stability but underlying financial challenges persist.
• **Employees:** Headcount reduction and termination of a research scientist and consulting scientist indicate job insecurity and impact on remaining seven employees.
• **Customers (future):** Potential for new cancer treatments if TTX-MC138 and other candidates are successfully developed and commercialized, offering hope for improved patient outcomes.
• **Suppliers/Vendors:** Reduced R&D and G&A expenses, along with restructuring of collaborations, may impact existing vendor relationships and future contracts.
• **Creditors:** The 'going concern' doubt and need for additional capital pose risks to creditors regarding the company's ability to meet its obligations.

Next Steps

• Continue advancing the Phase I/II clinical trial for TTX-MC138, including further dose escalation and patient enrollment.
• Negotiate a sponsored research agreement with Michigan State University for R&D activities.
• Seek additional capital through equity offerings, debt financings, governmental funding, collaborations, or strategic partnerships to fund operations beyond Q4 2025.
• Continue remediation efforts for identified material weaknesses in internal control over financial reporting.
• Hold the 2025 annual meeting of stockholders on August 29, 2025.

Key Dates

Recommendation

Despite some positive clinical trial progress and achieving Nasdaq compliance, the company faces severe financial distress. The significant increase in net loss, higher cash burn from operations, and the explicit 'substantial doubt' about its ability to continue as a going concern, with cash only sufficient into Q4 2025, present an extremely high-risk profile. The ongoing need for substantial capital raises, which will likely lead to significant shareholder dilution, and the potential for a total loss of investment in the event of restructuring, make this a 'sell' recommendation for a seasoned investor or institution. The fundamental financial health is precarious, overshadowing any clinical advancements.

Keywords

RNA therapeutics, oncology, cancer treatment, TTX-MC138, clinical trial, biopharmaceutical, SEC filing, 10-Q, Nasdaq listing, going concern, capital raise, preclinical development, drug delivery, metastatic cancer, microRNA-10b